# Allogene Therapeutics, Inc. (ALLO) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Allogene Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ALLO/mda/fy2025/): filed 2026-03-12; accession 0001628280-26-017242 (https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/ALLO/mda/fy2024/): filed 2025-03-13; accession 0001737287-25-000036 (https://www.sec.gov/Archives/edgar/data/1737287/000173728725000036/allo-20241231.htm)
- [FY 2023 MD&A](/company/ALLO/mda/fy2023/): filed 2024-03-14; accession 0001737287-24-000021 (https://www.sec.gov/Archives/edgar/data/1737287/000173728724000021/allo-20231231.htm)
- [FY 2022 MD&A](/company/ALLO/mda/fy2022/): filed 2023-02-28; accession 0001737287-23-000018 (https://www.sec.gov/Archives/edgar/data/1737287/000173728723000018/allo-20221231.htm)
- [FY 2021 MD&A](/company/ALLO/mda/fy2021/): filed 2022-02-23; accession 0001737287-22-000013 (https://www.sec.gov/Archives/edgar/data/1737287/000173728722000013/allo-20211231.htm)

Back to /company/ALLO/